IssuerAnnouncementDetailsV2Portlet
Actions
Jamjoom Pharmaceuticals Factory Co. Announces the Results of the Ordinary General Assembly Meeting, ( First Meeting )
| Element List | Explanation |
|---|---|
| Introduction | The Board of Directors of Jamjoom Pharmaceuticals Factory Company (the “Company”) is pleased to announce the results of the Ordinary General (First Meeting) Assembly held on Thursday 28/12/1445 H corresponding to 4/07/2024 G after the quorum for the validity of the meeting was completed. |
| City and Location of the General Assembly's Meeting | Company’s headquarters in Jeddah, via modern technology means. |
| Date of the General Assembly's Meeting | 2024-07-04 Corresponding to 1445-12-28 |
| Time of the General Assembly’s Meeting | 18:30 |
| Percentage of Attending Shareholders | 77.90% |
| Names of the Board of Directors' Members Present at the General Assembly's Meeting and Names of the Absentees | The meeting was attended by the following Board Members: 1- Mr. Mahmoud Yousuf Jamjoom (Chairman) 2- Mr. Ahmed Yousuf Jamjoom (Vice Chairman) 3- Mr. Faris Ibrahim Abdullah Al Ghannam (Member) 4- Mr. Mohammed Yousuf Jamjoom (Member) 5- Mrs. Alaa Yousuf Jamjoom (Member) 6- Mr. Georges P. Schorderet (Member) The following were unable to attend this meeting: 1- Mr. Yousuf Mohammed Salah Jamjoom (Member) 2- Mr. Noor Ahmed Kather Pasha Sheriff (Member) 3- Mr. Michel Marcel Jean-Marie Le Bars (Member) |
| Names of the Chairmen of the Committees Present at the General Assembly's Meeting or Members of such Committees Attending on Their Behalf | The following committee chairpersons attended the meeting: 1- Mr. Faris Ibrahim Abdullah Al Ghannam (Chairman of the Audit Committee). 2- Mr. Georges P. Schorderet (Chairman of the Nomination and Remuneration Committee). |
| Voting Results on the Items of the General Assembly's Meeting Agenda's | 1. Approval on the remunerations for the members of the Board of Directors and the Committees emanating from the Board of Directors, amounting to 2,324,500 Saudi Riyals for the fiscal year ended 31/12/2023. 2. Approval on the contracts and dealings conducted between the Company and Tegan Al-Fateh Factory Company Limited, in which Board Member Mr. Yousuf Mohammed Salah Jamjoom has an indirect interest. This involves an agreement to provide printing services (small cardboard boxes for medicines) under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 20,529,024 Saudi Riyals. 3. Approval on the contracts and dealings conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing travel booking services under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 11,244,436 Saudi Riyals. 4. Approval on the contracts and dealings that will be conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing advance payments for the year 2023 for travel booking services under prevailing commercial terms without preferential benefits, noting that the advance payment amounting to 4,553,644 Saudi Riyals has been paid for the year 2023 of which 509,602 Saudi Riyals has been paid for the year 2024. 5. Approval on the contracts and dealings that took place between the Company and Jamjoom Algeria Lildawa, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board Mr. Ahmed Yousuf Jamjoom, and the Board Member, Mr. Mohammed Yousuf Jamjoom, have an indirect interest. These transactions are for the purpose of operational expenses for the joint venture, under prevailing commercial terms and without preferential benefits, noting that the value of expenses for the year 2023 amounted to 821,147 Saudi Riyals. |
| Additional Information | The Board of Directors of Jamjoom Pharmaceuticals Factory Company would like to thank the respected shareholders for their participation and attendance of the Ordinary General Assembly Meeting (First Meeting). For any inquiries, please directly contact the Investor Relations Department through: Email: IR@jamjoompharma.com |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
Share
Company Performance
Key Parameters
Last Price 173.6
Net Change 3.0 (+1.76%)
Value Traded (Sar) 5,316,171.4
Volume Traded 30,756
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions